NCT07011732: A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- State
- Under way
- Phase
- Phase 3
- People
- 426 planned
- Started
- 10 Jul 2025
- Primary completion
- 24 Nov 2028
- Arms
- KarXT + KarX-EC
- Results
- None posted
- 10 Jun 2025: Trial registered
- 10 Jul 2025: Trial started